Is Choksi Laborator overvalued or undervalued?

As of 10 October 2025, Choksi Laborator's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 82.47, an EV to EBITDA of 13.39, and a PEG Ratio of 2.92, which suggest that while the company has a high valuation, it may be justified given its growth prospects.
In comparison to its peers, Choksi Laborator's PE Ratio is lower than Max Healthcare's 93.27 and Fortis Health's 86.96, both of which are classified as very expensive. Additionally, Apollo Hospitals, which is rated as attractive, has a PE Ratio of 70.15, further supporting the notion that Choksi Laborator is undervalued relative to its industry. Notably, the company's stock has outperformed the Sensex significantly over the past five years, with a return of 1516.01% compared to the Sensex's 103.66%, reinforcing its strong growth trajectory.